AKTX Celsus Therapeutics PLC

Akari Therapeutics to Participate in the Cantor Oncology & HemOnc Conference

Akari Therapeutics to Participate in the Cantor Oncology & HemOnc Conference

NEW YORK and LONDON, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that the company will participate in the investor-focused Cantor Oncology & HemOnc Conference on September 28, 2022. President and CEO Rachelle Jacques will take part in a conference panel, Addressing Challenges in Cell Therapy and Transplant, at 9:00 a.m. Eastern time and will attend 1:1 investor meetings.

About Akari Therapeutics

Akari Therapeutics, plc (Nasdaq: AKTX) is a biotechnology company developing advanced therapies for autoimmune and inflammatory diseases. Akari’s lead asset, investigational nomacopan, is a bispecific recombinant inhibitor of C5 complement activation and leukotriene B4 (LTB4) activity. Akari’s pipeline includes a Phase 3 clinical trial program investigating nomacopan for severe pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA), as well as pre-clinical research of long-acting PAS-nomacopan in geographic atrophy (GA). For more information about Akari, please visit .

Investor Contact:

Mike Moyer

LifeSci Advisors

(617) 308-4306

Media Contact:

Eliza Schleifstein

Schleifstein PR   

(917) 763-8106



EN
22/09/2022

Underlying

AKTXCelsus Therapeutics PLC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Celsus Therapeutics PLC

 PRESS RELEASE
Free
AKTX Celsus Therapeu...

Akari Therapeutics Announces $5 Million Financing, Including Concurren...

Akari Therapeutics Announces $5 Million Financing, Including Concurrent Registered Direct Offering and Private Placement Priced At-Market New cash portion of offering includes >20% participation from Directors, Officers and Executive Management TAMPA, Fla. and LONDON, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) (the “Company”), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 12,607,487 of the Company’s Americ...

1h / 1m 1 EN
 PRESS RELEASE
Free
AKTX Celsus Therapeu...

Akari Therapeutics Highlights Preclinical Data Demonstrating Therapeut...

Akari Therapeutics Highlights Preclinical Data Demonstrating Therapeutic Potential of Lead Candidate, AKTX-101, for Hard-to-Treat K-Ras Mutant Pancreatic Cancer Data highlights the ability of Akari’s Trop2 ADC, AKTX-101, to kill K-Ras G12V mutated cancer cell lines in preclinical models, potentially addressing one of the most lethal cancers with the lowest survival rates  The K-Ras G12V mutation is the oncogenic driver for 1/3 of all pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer Significant unmet need in pancreatic cancer where median overall survival ...

December 9, 2025 1 EN
 PRESS RELEASE
Free
AKTX Celsus Therapeu...

Akari Therapeutics Provides Corporate Update and Highlights its ADC Pa...

Akari Therapeutics Provides Corporate Update and Highlights its ADC Payload Innovation Expected to Drive Value in New CEO Corner Segment Access the Akari CEO Corner  TAMPA, Fla. and LONDON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payloads for antibody drug conjugates (ADCs), today announced the publication of a new CEO Corner segment, now available on the . For this segment, Abizer Gaslightwala, CEO of Akari, provides a corporate update highlighting the Company’s recent progress and key growth opportunit...

December 4, 2025 1 EN
 PRESS RELEASE
Free
AKTX Celsus Therapeu...

Akari Therapeutics Announces Release of the Next CEO Corner Segment

Akari Therapeutics Announces Release of the Next CEO Corner Segment Access the Akari CEO Corner  BOSTON and LONDON, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payloads for antibody drug conjugates (ADCs), today announced the next CEO Corner segment has been published on the . For this CEO Corner segment, Abizer Gaslightwala, CEO of Akari, provides an overview of the Company’s innovation in ADCs, highlighting its novel PH1 payload and its dual mechanism of action. Additionally, Mr. Gaslightwala discusses the...

November 25, 2025 1 EN
 PRESS RELEASE
Free
AKTX Celsus Therapeu...

Akari Therapeutics Appoints Biotech Finance Leader, Kameel D. Farag as...

Akari Therapeutics Appoints Biotech Finance Leader, Kameel D. Farag as Interim Chief Financial Officer More than 20 years of financial and operational leadership in biopharma, including $170M+ in capital raised, global commercialization experience, and a proven track record scaling companies from preclinical to clinical milestones TAMPA and LONDON, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payloads for antibody drug conjugates (ADCs), today announced the appointment of Kameel D. Farag as its Interim Chie...

November 18, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch